Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y577
UPID:
TRI17_HUMAN
Alternative names:
RING finger protein 16; RING-type E3 ubiquitin transferase TRIM17; Testis RING finger protein; Tripartite motif-containing protein 17
Alternative UPACC:
Q9Y577; B4DVJ2; Q5VST8
Background:
E3 ubiquitin-protein ligase TRIM17, also known as RING finger protein 16, plays a pivotal role in neuronal apoptosis, selective autophagy, and cell proliferation. It regulates the degradation of proteins such as ZWINT and MCL1, influencing cell growth and survival. TRIM17's interaction with BECN1 and NFAT transcription factors further underscores its regulatory complexity in cellular processes.
Therapeutic significance:
Understanding the role of E3 ubiquitin-protein ligase TRIM17 could open doors to potential therapeutic strategies. Its involvement in key cellular mechanisms like apoptosis and autophagy highlights its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.